The phase 3 clinical trial (NCT03617731) succeeded in testing combinations of blocking Abs against CD38 on plasma cells (isatuximab) with global protein-degrading agents (lenalidomide, bortezomib) and dexamethasone in patients with multiple myeloma [55]. Here, CD38 is linked to plasma cell myeloma.